Patents Examined by Lynn Bristol
  • Patent number: 10358500
    Abstract: Disclosed herein are humanized anti-LGR5 antibodies for the treatment of cancer. Antibodies disclosed herein may bind LGR5 without disrupting LGR5-RSPO1 binding or signaling, and may disrupt LGR5 signaling through Wnt that is independent of RSPO1. Also disclosed are heavy and light chain polypeptide sequences for the biding of LGR5, for example without disrupting LGR5-RSPO binding or signaling.
    Type: Grant
    Filed: December 14, 2016
    Date of Patent: July 23, 2019
    Assignee: BIONOMICS INC.
    Inventors: Christopher L. Reyes, Peter Chu, Kristen M. Smith, Lioudmila A. Campbell, Farbod Shojaei, John Thomas Norton
  • Patent number: 10357514
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of CD19, e.g., by administering a recombinant T cell comprising the CD19 CAR as described herein, in combination with a kinase inhibitor, e.g., a kinase inhibitor described herein. The invention also provides kits and compositions described herein.
    Type: Grant
    Filed: April 7, 2015
    Date of Patent: July 23, 2019
    Assignees: The Trustees of the University of Pennsylvania, Novartis AG
    Inventors: Carl H. June, David L. Porter, Marcela Maus, Mariusz Wasik, Saar Gill, Joseph Fraietta, Marco Ruella, John Byrd, Jason Dubovsky, Amy Johnson, Natarajan Muthusamy, Saad Kenderian, Joan Mannick, David Glass, Leon Murphy, Jennifer Brogdon, William Raj Sellers
  • Patent number: 10358493
    Abstract: The present disclosure relates to a novel bispecific protein complex and a method of using the complexes to screen for synergistic or novel biological function. The bispecific format is particularly suitable for high-throughput screening because all of its components can be expressed from cells as individual units and the units can be assembled simply by mixing without employing conjugation or coupling chemistry.
    Type: Grant
    Filed: May 28, 2015
    Date of Patent: July 23, 2019
    Inventors: Helene Margaret Finney, Stephen Edward Rapecki, Michael John Wright
  • Patent number: 10323086
    Abstract: The invention concerns anti-NGF antibodies (such as anti-NGF antagonist antibodies), and polynucleotides encoding the same. The invention further concerns use of such antibodies and/or polynucleotides in the treatment and/or prevention of pain, including post-surgical pain, rheumatoid arthritis pain, and osteoarthritis pain.
    Type: Grant
    Filed: October 6, 2016
    Date of Patent: June 18, 2019
    Assignee: Rinat Neuroscience Corp.
    Inventors: Arnon Rosenthal, David Louis Shelton, Patricia Ann Walicke
  • Patent number: 10323081
    Abstract: Provided are antibody variants having decreased or increased ability to mediate complement-dependent cytotoxicity (CDC) due to the presence or absence of C-terminal lysines of their heavy chains. Also provided are methods of generating such antibodies, as well as nucleotide constructs and host cells suitable for the production of such antibodies.
    Type: Grant
    Filed: July 6, 2012
    Date of Patent: June 18, 2019
    Assignee: GENMAG A/S
    Inventors: Paul Parren, Patrick Van Berkel, Ewald T. J. Van Den Bremer
  • Patent number: 10323099
    Abstract: Multispecific antibodies based on antibodies that share a common light chain are described herein. The multispecific antibodies include: modified heavy chains having, by domain exchange, a common light chain variable domain VL; and two modified light chains having, by domain exchange, variable heavy chain domains of a first antibody (VH1) and a second antibody (VH2), wherein one light chain is of kappa isotype and one light chain is of lambda isotype. The present invention also relates to methods for the manufacture of such antibodies and their use.
    Type: Grant
    Filed: April 7, 2016
    Date of Patent: June 18, 2019
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Peter Bruenker, Christiane Neumann, Christian Klein, Ekkehard Moessner, Wolfgang Schaefer
  • Patent number: 10314910
    Abstract: Provided is a method for enhancing the potency of a targeted cancer immunotherapy in a subject by using a superantigen in combination with an immunopotentiator (for example, a PD-1 inhibitor).
    Type: Grant
    Filed: January 10, 2017
    Date of Patent: June 11, 2019
    Assignee: NeoTX Therapeutics Ltd.
    Inventors: Asher Nathan, Michal Shahar
  • Patent number: 10316101
    Abstract: The present invention relates to Chimeric Antigen Receptors (CAR) that are recombinant chimeric proteins able to redirect immune cell specificity and reactivity toward selected membrane antigens, and more particularly in which extracellular ligand binding is a scFV derived from a BCMA monoclonal antibody, conferring specific immunity against BCMA positive cells. The engineered immune cells endowed with such CARs are particularly suited for treating lymphomas, multiple myeloma and leukemia.
    Type: Grant
    Filed: April 13, 2015
    Date of Patent: June 11, 2019
    Assignee: CELLECTIS
    Inventor: Roman Galetto
  • Patent number: 10294305
    Abstract: Preparations and methods for treating a GD2 positive cancer by administering a preparation comprising an anti-GD2 antibody to a patient, wherein the patient is not concomitantly treated with Interleukin-2 (IL-2), and wherein one or more treatment periods with the antibody may be preceded, accompanied, and/or followed by one or more treatment periods with a retinoid.
    Type: Grant
    Filed: February 18, 2014
    Date of Patent: May 21, 2019
    Inventors: Hans Loibner, Oliver Mutschlechner, Ruth Ladenstein, Isabel Klier
  • Patent number: 10287340
    Abstract: The invention provides single domain antibodies and derivatives thereof that bind antigens of interest, which are stable, soluble, and do not tend to aggregate. The invention also provides methods for constructing a dAb library and methods for screening dAb libraries to identify the dAb of the invention. The invention also provide methods of treating or preventing conditions by antigen neutralization by administering the dAbs of the invention.
    Type: Grant
    Filed: September 28, 2015
    Date of Patent: May 14, 2019
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Dimiter S. Dimitrov, Weizao Chen
  • Patent number: 10287360
    Abstract: The present invention relates to anti-Epidermal Growth Factor Receptor (EGFR) conformational single domain antibodies and uses thereof in particular in the therapeutic and diagnostic field.
    Type: Grant
    Filed: May 22, 2015
    Date of Patent: May 14, 2019
    Assignees: INSERM (Institut National de la Santé et de la Recherche Médicale, Université d' Aix-Marseille, Centre National de la Recherche Scientifique (CNRS), CISBIO Bioassays, Institut Jean Paoli & Irene Calmettes
    Inventors: Daniel Baty, Patrick Chames, Damien Nevoltris, Gérard Mathis
  • Patent number: 10280211
    Abstract: The present invention relates to methods for screening and producing polypeptides that immunospecifically bind to an antigen, which: polypeptides comprise binding domains that are derived from rabbit immunoglobulin. Using rabbit antibody heavy-chain or light-chain scaffolds, the methods of the invention allow identification of novel CDR loops and framework regions that confer enhanced stability and/or affinity to isolated immunoglobulin variable domains, in particular, relative to those derived from rodent antibodies. The enhanced stability and/or affinity of the variable domains of the invention permit their use in the production research tools or therapeutic immunospecific polypeptides, including single domain immunospecific polypeptides, i.e., comprising one of a VH or VL domain.
    Type: Grant
    Filed: April 30, 2008
    Date of Patent: May 7, 2019
    Inventors: João Manuel Braz Goncalves, Frederico Nuno Castanheira Aires Da Silva
  • Patent number: 10253091
    Abstract: By altering amino acid sequences, the present inventors successfully produced constant regions that can confer antibodies with particularly favorable properties for pharmaceutical agents. When used to produce antibodies, the altered constant regions produced according to the present invention significantly reduce heterogeneity. Specifically, the antibody homogeneity can be achieved by using antibody heavy chain and light chain constant regions introduced with alterations provided by the present invention. More specifically, the alterations can prevent the loss of homogeneity of antibody molecules due to disulfide bond differences in the heavy chain. Furthermore, in a preferred embodiment, the present invention can improve antibody pharmacokinetics as well as prevent the loss of homogeneity due to C-terminal deletion in antibody constant region.
    Type: Grant
    Filed: April 7, 2015
    Date of Patent: April 9, 2019
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Tomoyuki Igawa, Taichi Kuramochi, Atsuhiko Maeda, Hirotake Shiraiwa
  • Patent number: 10253106
    Abstract: This invention relates to the use of monoclonal and polyclonal antibodies that specifically bind to and have the ability in the alternative to become internalized by cells expressing folate receptor alpha (FRA) and to induce an immune effector activity such as antibody-dependent cellular cytotoxicity. The antibodies are useful in specific delivery of pharmacologic agents to FRA-expressing cells as well as in eliciting an immune-effector activity particularly on tumor cells and precursors. The invention is also related to nucleotides encoding the antibodies of the invention, cells expressing the antibodies; methods of detecting cancer cells; and methods of treating cancer using the antibodies.
    Type: Grant
    Filed: November 8, 2016
    Date of Patent: April 9, 2019
    Assignee: Eisai, Inc.
    Inventors: Luigi Grasso, Nicholas C. Nicolaides, Philip M. Sass
  • Patent number: 10238742
    Abstract: Cancer cells with defects in DNA repair are highly susceptible to DNA-damaging agents, but delivery of therapeutic agents into cell nuclei can be challenging. A sub-set of autoantibodies having nucleolytic activity are capable of nuclear penetration. These antibodies can be used as therapeutic agents targeted towards DNA repair-deficient malignancies.
    Type: Grant
    Filed: June 25, 2015
    Date of Patent: March 26, 2019
    Assignees: Yale University, The United States of America as Represented by the Department of Veterans Affairs
    Inventors: James E. Hansen, Richard H. Weisbart, Philip W. Noble
  • Patent number: 10232040
    Abstract: Provided herein are methods of treating non-small cell lung cancers comprising administering an effective amount of MEDI4736 or an antigen-binding fragment thereof and tremelimumab or an antigen-binding fragment thereof.
    Type: Grant
    Filed: May 12, 2015
    Date of Patent: March 19, 2019
    Assignee: MEDIMMUNE, LLC
    Inventors: Rajesh Narwal, Paul Robbins, Joyson Karakunnel, Mohammed Dar
  • Patent number: 10233251
    Abstract: There is disclosed compositions and methods relating to or derived from anti-CD137 antibodies. More specifically, there is disclosed fully human antibodies that bind CD137, CD137-antibody binding fragments and derivatives of such antibodies, and CD137-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating a disease requiring either stimulation of immune responses or suppression. Diseases amenable to treatment is selected from the group consisting of cancers, autoimmune diseases and viral infections.
    Type: Grant
    Filed: February 22, 2016
    Date of Patent: March 19, 2019
    Assignee: Sorrento Therapeutics, Inc.
    Inventors: John Dixon Gray, Heyue Zhou
  • Patent number: 10227413
    Abstract: Provided herein are antigen-binding proteins (ABPs) that selectively bind to NRP-1 and its isoforms and homologs, and compositions comprising the ABPs. Also provided are methods of using the ABPs, such as therapeutic and diagnostic methods.
    Type: Grant
    Filed: February 20, 2018
    Date of Patent: March 12, 2019
    Assignee: Potenza Therapeutics, Inc.
    Inventors: Daniel Hicklin, Cynthia Seidel-Dugan, William Winston, Jose-Andres Salmeron-Garcia, Nels P. Nielson, Heather Brodkin
  • Patent number: 10221251
    Abstract: The present disclosure relates to a symmetric bispecific antibody of the class IgG4 comprising two heavy chains which each comprise a variable domain, CH1 domain and a hinge region, wherein in each heavy chain: the cysteine in the CH1 domain which forms an inter-chain disulphide bond with a cysteine in a light chain is substituted with another amino acid; and optionally one or more of the amino acids positioned in the upper hinge region is substituted with cysteine, wherein the constant region sequence of each heavy chain is similar or identical and the variable region in each heavy chain is different, formulations comprising the same, the use of each of the above in treatment and processes for preparing said antibodies and formulations.
    Type: Grant
    Filed: February 22, 2013
    Date of Patent: March 5, 2019
    Assignee: UCB Biopharma SPRL
    Inventors: David Paul Humphreys, Shirley Jane Peters
  • Patent number: 10214584
    Abstract: The present invention aims to provide a pharmaceutical composition for cancer treatment, which comprises a novel monoclonal antibody binding to SLC6A6 or its extracellular region and a chemotherapeutic agent conjugated therewith, as well as a therapeutic method in which the monoclonal antibody or a therapeutic agent composed of the monoclonal antibody conjugated with a chemotherapeutic agent is used in combination with a chemotherapeutic agent. The present invention provides a pharmaceutical composition comprising an antibody conjugate configured such that a monoclonal antibody having higher affinity than conventional antibodies and recognizing native SLC6A6 or a native polypeptide of an extracellular region of SLC6A6 is conjugated with an anticancer agent or the like having activity against cancer and other hyperproliferative diseases.
    Type: Grant
    Filed: January 15, 2015
    Date of Patent: February 26, 2019
    Inventors: Hiroyuki Satofuka, Kensuke Ohse, Shigeki Mukobata, Hirotada Akiyama, Masaya Ohtsu, Yoko Okabe, Yasufumi Murakami